Results 91 to 100 of about 33,958 (207)

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

The Importance of Pediatric Nonhuman Primate Models in Translational HIV Research

Journal of Medical Primatology, Volume 55, Issue 2, April 2026.
ABSTRACT Despite extraordinary global progress in the prevention and treatment of HIV, pediatric HIV remains a significant and under‐addressed component of the global epidemic. In her keynote presentation at the Pediatric Nonhuman Primate (NHP) Workshop in October 2024, Dr.
Ann Chahroudi
wiley   +1 more source

CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection

Journal of Virology
The viral reservoir in long-lived memory CD4+ cells, established in the early stages of HIV infection, represents the main obstacle to an HIV cure. Some strategies being developed to target the reservoir rely on rendering HIV-1 envelope glycoproteins ...
Shilei Ding, Alexandra Tauzin, Delia Pinto-Santini, Sayan Dasgupta, Derek Yang, William D. Tolbert, Monika Chandravanshi, Mehdi Benlarbi, Myriam Verly, Javier R. Lama, Donna M. Huryn, Amos B. Smith, Marzena Pazgier, Andrés Finzi, Ann Duerr   +14 more
doaj   +1 more source

Changing Pattern of HDV Infection in Italy Over 40 Years; the Current Scenario and the Impending Challenge

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since the initial description of HDV, in the last four decades Italy has witnessed a profound decline of the infection driven by HBV vaccination, contrasted however by the reconstitution of a viral reservoir through migratory flows from endemic HDV areas; in parallel, the medical scenario has changed, resulting in different clinical outcomes ...
Gian Paolo Caviglia, Tommaso Stroffolini
wiley   +1 more source

Adult T‐cell leukemia/lymphoma in French Guiana (1990–2019): Epidemiology, clinical features, and HTLV‐1 genetic diversity in the two main ethnic populations

International Journal of Cancer, Volume 158, Issue 6, Page 1528-1540, 15 March 2026.
What's new? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy, Patricia Tortevoye, Balthazar Ntab, Gabriel Carles, Jean‐Pierre Droz, Pierre Couppié, Giovanni Begliomini, Jean‐Francois Carod, N'detodji‐Bill Wankpo, Karim Abdelmoumen, Philippe V. Afonso, Olivier Cassar, Antoine Talarmin, Olivier Hermine, Loïc Epelboin, Ambroise Marçais, Antoine Gessain   +16 more
wiley   +1 more source

Latency Reversing Agents and the Road to an HIV Cure

Pathogens
HIV-1 infection cannot be cured due to the presence of HIV-1 latently infected cells. These cells do not produce the virus, but they can resume virus production at any time in the absence of antiretroviral therapy. Therefore, people living with HIV (PLWH)
Louis Tioka, Rafael Ceña Diez, Anders Sönnerborg, Maarten A. A. van de Klundert   +3 more
doaj   +1 more source

Attenuated Bacteria‐Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu, Junhong Yao, Jiaxin Deng, Minjie Zhou, Kaiyue Shen, Shishuo Sun, Xiaoge Gao, Qing Zhang, Haiheng Xu   +8 more
wiley   +1 more source

Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency

Frontiers in Cellular and Infection Microbiology, 2023
Alexander O. Pasternak, Olivier Rohr, Olivier Rohr, Carine Van Lint, Anna Kula-Pacurar   +4 more
doaj   +1 more source

CD4‐Based Chimeric Antigen Receptor (CAR)‐T Cells With Resistance to HIV‐1 Infection and Enhanced Anti‐HIV Efficacy: Covalent Interaction Between CD4‐CAR and HIV‐1 Envelope Glycoprotein

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT The current highly active antiretroviral therapy (HAART or ART) effectively suppresses de novo HIV‐1 infection but fails to eliminate HIV reservoir cells, which leads to rapid viral rebound upon ART cessation. Chimeric antigen receptor (CAR) T cells engineered to target HIV‐1 Env⁺ cells offer a promising strategy to eliminate or control these ...
Yaoxian Lou, Xiuting He, Guangming Li, Martin Sikhondze, Jianping Ma, Hongwei Du, Xin Ouyang, Gianpietro Dotti, Mohammad Sajadi, Lishan Su   +9 more
wiley   +1 more source

Corrigendum: Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency

Frontiers in Cellular and Infection Microbiology, 2023
Alexander O. Pasternak, Olivier Rohr, Olivier Rohr, Carine Van Lint, Anna Kula-Pacurar   +4 more
doaj   +1 more source